Jim Crowell’s Post

View profile for Jim Crowell, graphic

Investor, Operator, and Advisor in Fitness & Wellness

It's interesting how battle lines have been drawn so firmly on GLP1's - Ozempic, WeGovy, etc... - particularly around the recent data suggesting that the US Obesity Rate fell for the first time in a long time due, likely in no small part, to GLP1's. There is a lot of "Is this amazing," or is this "a huge problem" going on in the fitness/wellness/general world. Perhaps we don't wants to hear or say this, but we need to look at this with more nuance because IT DEPENDS! In a world that is heavily dominated by soundbites, memes, and shallow-depth thought going viral, I find myself increasingly in conversations where the reality is far more complex than one sentence, and I don't think it's optimal to have a stance so firm that it fails to take into account the myriad of volatility associated with health. For ex, 1. Do we know the long-term effects of GLP1's for weight loss clients? Absolutely not because they haven't been out long enough. We can speculate, but let's make sure to say it's speculation 2. Do the pharma companies have our best interests at heart? In any large organization there are clearly champions of the customer as well as champions for the companies' bottom lines. 3. Do GLP1's cause potential issues with loss of muscle mass? This appears to be true in the studies that have been run. However, if somebody can lose a lot of weight where they otherwise couldn't have before, is it a net positive? IT DEPENDS! 4. Is a 1.6% decrease in obesity rate a new trend? By definition, it is not because it is only one data point in a multi-year/decade history, particularly when 10 years ago we were in the mid/high 30%'s. Can we speculate about if it's a good/bad thing? We sure can 5. Will all humans respond to GLP1's the same way? Absolutely not - physically, mentally, emotionally (and also financially) matters in how people react to medications like this. 6. Will the "wolves" come into this market because it's exploding, creating a negative outcomes? Who knows, but we are seeing seriously large numbers of new players enter the space Like all complex and challenging situations (health / obesity / meds), let's make sure we ask great questions to smart/credible people to CONTINUE opening our eyes more and more good and bad. It's a fact that we already have an emotional opinion (that darn human behavior thing haha) but in a topic this big, we owe it to ourselves to dig more deeply https://lnkd.in/dS4sy-J8 https://lnkd.in/dNKg-NJv

Obesity prevalence among US adults falls slightly to 40%, remains higher than 10 years ago: CDC

Obesity prevalence among US adults falls slightly to 40%, remains higher than 10 years ago: CDC

abcnews.go.com

Sean Pastuch

Owner and Founder at Active Life

2mo

Generally, I find people are asking the wrong questions. I’ve spent much more time than a person who doesn’t prescribe them, doesn’t use them, doesn’t have family or friends using them, should. I think the questions should be around who are they good for, who are they less good for, who are they bad for? And What should happen to doctors who write irresponsible scripts to people in the accepted “bad for” category? Once we have that sorted, and the proverbial bleeding has stopped, let’s find the source of how we got to needing them in the first place, and unwind that.

Melissa Wilson

Creating cutting-edge solutions for our clients!!

2mo

I struggle with this one because GLP1 in itself is a peptide or a chain of amino acids which are generally believed to be safe. I did hear a podcast the other day from an MD that said that the muscle mass loss is typically from a doctor prescribing too high of a dose and losing weight too rapidly, which isn’t healthy. However, what makes me nervous is that people could use this as a way to eat whatever they want (S.A.D. Foods laced with chemicals and low nutrition). Thin or avoiding obesity does not equal healthy, so as one component of treatment for an overweight individual - it’s definitely VERY exciting.

Taylor Gabhart

Dedicated to educating and empowering health and fitness professionals. 👩🏻💻

2mo

Throughly enjoyed listening to Maintenance Phase's podcast episode on Ozempic. Their stance is if it works for you, go for it! But as a society we shouldn't make it a catch all. They dive the medical trials, concerns on shortages of the drugs for other populations who need it and fat bias in our society as a whole. It was an interesting listen! They use some colorful language as a warning for anyone who wants to listen.

Thanks for sharing. I had been curious your thoughts on the GLP1 phenomenon. While they can be a wonderful tool if used properly, we won’t know the long term effects for a while yet and my fear is they just cover up the bigger issue which doesn’t get resolved.

Michael Hosking, Ph.D.

Creator of Revocycle Mind and Body Cycling/Education; Exercise and Mental Health, Mindful Fitness, Neuroscience of Exercise and the Brain

2mo

I think you capture many of the issue well here. In my opinion, it we put our focus-within the fitness industry-on customer wellbeing (not necessarily body weight/size, not necessarily muscle mass, not slimming down for summer, etc.) we'll be on the best path. For example, do we have a plan or message for those who come to us because of the medications, but then, as many do, stop them. This speaks to the need to think on the level of holistic health and exercise for that.

Like
Reply
Pete McCall

Enhancing value and engaging employees through effective training and development programs. Author. Public Speaker.

2mo

Jim Due to the variability of the physiology of the human body and because there are so many factors that could effect an outcome, EVERY answer to a question about exercise starts with, "That depends." GLP1s are here, and point #3 is a big concern, the data shows up to 50% of weight loss from muscle mass (GLP1s affect glucose metabolism, glycogen is stored in muscle cells, hence, the drugs will influence muscle mass). Operators need to accept that members will be taking the drugs and develop a plan for how best to meet their needs; that's where a program like RAMP by Rocco Boulay comes in. RAMP provides a systematic method of strength training that could minimize muscle loss for individuals taking GLP1s.

See more comments

To view or add a comment, sign in

Explore topics